论文部分内容阅读
目的制备预防人单纯疱疹病毒感染的疫苗。方法扩增人单纯疱疹病毒Ⅱ型的gD基因,克隆入载体,导入大肠埃希菌表达系统,表达、分离、纯化抗原蛋白,然后进行小鼠动物免疫实验,测定小鼠的抗体水平;最后攻毒实验,观察小鼠的病理变化和死亡率。结果免疫后,gD抗原和IFN-γ联合免疫组小鼠体内产生抗体最高,其次gD抗原免疫组。生理盐水组小鼠病理变化出现最早也最重,且死亡最多;gD抗原免疫组小鼠病理变化出现较晚,症状也轻,死亡也少;gD抗原和IFN-γ联合免疫组小鼠无死亡。结论制备小鼠抗人单纯疱疹病毒的疫苗是可行的。此疫苗是否能刺激人体产生抗单纯疱疹病毒的抗体,是否对人有免疫效果,还有待于进一步研究。
Objective To prepare a vaccine against human herpes simplex virus infection. Methods The gD gene of human herpes simplex virus type Ⅱ was amplified, cloned into vector, introduced into Escherichia coli expression system, expressed, isolated and purified antigen protein, and then immunized mice to determine the antibody level in mice. Finally, Toxicity tests were performed to observe the pathological changes and mortality of mice. Results After immunization, gD antigen and IFN-γ combined immunized mice produced the highest antibody in vivo, followed by gD antigen immunohistochemistry. The pathological changes of the mice in the saline group were the earliest and the heaviest, with the highest death rate. The pathological changes of the mice immunized with gD antigen appeared later, with less symptoms and fewer deaths. There was no death in the gD antigen and IFN-γ combined immunized mice . Conclusion The preparation of anti-human herpes simplex virus vaccine is feasible. Whether this vaccine can stimulate the body to produce anti-herpes simplex virus antibody is immune to human effect remains to be further studied.